Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Miricorilant in Diabetes Mellitus, Type 2: NCT06108219 Clinical Landscape Report 2026
15 October 2026
NCT06108219 clinical landscape for Diabetes Mellitus, Type 2: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Allogeneic cytomegalovirus-specific cytotoxic T lymphocytes(The Ohio State University) in Glioblastoma Multiforme: ACTRN12623001126606 Clinical Landscape Report 2026
15 October 2026
ACTRN12623001126606 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Sufenidone in Idiopathic Pulmonary Fibrosis: NCT06125327 Clinical Landscape Report 2026
15 October 2026
NCT06125327 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Acetyl-L-carnitine in Amyotrophic Lateral Sclerosis: NCT06126315 Clinical Landscape Report 2026
15 October 2026
NCT06126315 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
PEP-CMV vaccine(The University of New South Wales) in Glioblastoma Multiforme: NCT06132438 Clinical Landscape Report 2026
15 October 2026
NCT06132438 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Axatilimab-csfr in Idiopathic Pulmonary Fibrosis: NCT06132256 Clinical Landscape Report 2026
15 October 2026
NCT06132256 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Sufenidone in Idiopathic Pulmonary Fibrosis: NCT06135363 Clinical Landscape Report 2026
15 October 2026
NCT06135363 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Metformin Hydrochloride/Pioglitazone Hydrochloride in Fibrosis, Liver: NCT06135584 Clinical Landscape Report 2026
15 October 2026
NCT06135584 clinical landscape for Fibrosis, Liver: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Trimetazidine Hydrochloride in Metabolic Dysfunction Associated Steatohepatitis: NCT06140953 Clinical Landscape Report 2026
15 October 2026
NCT06140953 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
CAR-001 in Glioblastoma Multiforme: NCT06150885 Clinical Landscape Report 2026
15 October 2026
NCT06150885 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
XS-005 (Xellsmart) in Glioblastoma: NCT06147505 Clinical Landscape Report 2026
15 October 2026
NCT06147505 clinical landscape for Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
XON-7 in Ovarian Cancer: NCT06154291 Clinical Landscape Report 2026
15 October 2026
NCT06154291 clinical landscape for Ovarian Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.